Superworth

Tyra Biosciences price to book ratio TYRA

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
3.6×
5-year median
2.4×
Against its 5-year history
77th
percentile: 0 is its lowest day, 100 its highest
5-year range
0.8× to 8.2×
Peer median
2.5×

Tyra Biosciences' price to book ratio is 3.6× as of Nov 2, 2026.

That is above its 5-year median of 2.4×, higher than on 77% of days in the last 5 years.

Over that time it ranged from 0.8× in Jun 2022 to 8.2× in Apr 2026.

The median for 10 large drugmakers of a similar size is 2.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.6×3.1×8.2×
20254.9×1.2×4.9×
20242.0×2.0×4.6×
20232.7×1.1×3.0×
20221.2×0.8×1.9×
20211.9×1.7×3.8×

Against its peers

Companies in Drug Manufacturers - General nearest Tyra Biosciences' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Tyra Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.